Welcome to our dedicated page for Datameds AI news (Ticker: MEDS), a resource for investors and traders seeking the latest updates and insights on Datameds AI stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Datameds AI's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Datameds AI's position in the market.
Summary not available.
TRxADE HEALTH INC. (NASDAQ:MEDS) will release its financial results for the first quarter of 2023 on May 8, 2023, after market close. The results will be discussed in a conference call at 5:00 p.m. Eastern time on the same day. Interested participants can join via a toll-free U.S. number or an international dial-in. TRxADE focuses on optimizing the retail pharmacy experience, utilizing technology to enhance drug procurement and patient engagement. The company serves over 14,500 members, promoting price transparency and offering telehealth services under the Bonum Health brand. A playback of the conference call will be accessible until June 8, 2023, providing further insights into the company's financial performance.
TRxADE Health, a digital healthcare services IT company, reported a 16% revenue increase to $11.4 million for the fiscal year 2022, up from $9.9 million in 2021. Key growth drivers included a 10% increase in revenues from the TRxADE Platform and a 46% rise from Trxade Prime, despite a 29% revenue decline in its Community Specialty Pharmacy unit. The firm's gross profit remained steady at 48%, and net losses narrowed to $3.9 million, down from $5.3 million in 2021. The company expanded its registered users by 8%, totaling over 14,400. A conference call is scheduled for March 27, 2023, to discuss these results.
TRxADE HEALTH INC. (NASDAQ:MEDS) plans to release its financial results for the fourth quarter and year-end 2022 on March 27, 2023, after market close. A conference call will follow at 5:30 p.m. Eastern time to discuss results and allow for a Q&A session. The company focuses on disease health IT by enhancing the retail pharmacy experience through optimized drug procurement and patient engagement. TRxADE serves over 14,400 members in the U.S. through its drug procurement marketplace and telehealth services under the Bonum Health brand. Investors can access the call through U.S. and international dial-ins or via webcast.
TRxADE HEALTH, INC. (NASDAQ:MEDS) announced a preferred telemedicine services agreement via its subsidiary Bonum Health with an independent group purchasing organization (GPO). This partnership aims to provide significant discounts to over 100 pharmacies in the northeastern U.S., enhancing access to telehealth services for uninsured and under-insured patients. The initiative responds to trends showing independent pharmacies losing clientele to larger competitors like CVS and Walgreens. The company’s strategy focuses on business-to-business opportunities, aiming to bolster its pharmacy network and improve operational performance.
TRxADE HEALTH, INC. (NASDAQ: MEDS) reported its Q3 2022 financial results, showing a 6% decline in revenues to $2.4 million compared to Q3 2021. Despite this, the TRxADE Platform revenues rose by 6% for the quarter and 10% for the year-to-date. Gross profit increased to $1.4 million, representing 58% of revenue, up from 50% a year prior. The net loss decreased to ($0.5 million) or ($0.06) per share from a ($1.3 million) loss in Q3 2021. The company added 291 new members in Q3, totaling 14,100+ registered members. Management emphasizes ongoing strategic partnerships and innovation efforts.
Summary not available.
TRxADE HEALTH INC. (NASDAQ:MEDS) plans to release its financial results for Q3 2022 after market close on November 7, 2022. The results will be shared in a press release following the close of regular trading hours. Management will also conduct a conference call at 5:00 p.m. Eastern time on the same day to discuss the financial results and answer questions from participants. TRxADE HEALTH aims to enhance the retail pharmacy experience through improved drug procurement and patient engagement.
TRxADE HEALTH, INC. (NASDAQ:MEDS) announced a securities purchase agreement to raise approximately $1.8 million via a registered direct offering and concurrent private placement. The company plans to sell 1,521,740 shares of common stock at an effective price of $1.15 per share. Additionally, warrants to purchase up to 2,663,045 shares will be issued, exercisable upon shareholder approval at an exercise price of $1.50. The offering is expected to close around October 7, 2022.
TRxADE HEALTH, INC. (NASDAQ: MEDS) announced the appointment of Jeff Newell to its Board of Directors on October 3, 2022. Newell, previously an advisor, brings over 40 years of healthcare experience and is expected to enhance the company's strategic initiatives. The Board believes his expertise will be valuable in optimizing relationships within the pharmaceutical sector. Chairman Suren Ajjarapu emphasized the aim of fostering long-term growth and building stockholder value through this leadership change.